CytoMed Therapeutics Limited Ordinary Shares - GDTC STOCK NEWS

Welcome to our dedicated page for CytoMed Therapeutics Ordinary Shares news (Ticker: GDTC), a resource for investors and traders seeking the latest updates and insights on CytoMed Therapeutics Ordinary Shares stock.

CytoMed Therapeutics Limited, established in 2018, is a Singapore-based biopharmaceutical company spun off from the Agency for Science, Technology and Research (A*STAR). The company leverages its proprietary technologies to develop groundbreaking cell-based immunotherapies for the treatment of various cancers. CytoMed Therapeutics focuses on utilizing patented gamma delta (γδ) T cell and natural killer (NK) cell-based therapies, creating 'off-the-shelf' solutions aimed at a wide range of cancers. Their innovative approach also includes generating induced pluripotent stem cells (iPSCs) to develop cellular therapeutics tailored to customer needs.

The company’s cutting-edge developments are inspired by the success of CAR-T cells in treating hematological malignancies and addressing the limitations and challenges of applying CAR-T principles to solid tumors. CytoMed operates primarily in Singapore and Malaysia, with the latter being a significant revenue contributor.

Recently, CytoMed Therapeutics announced significant advancements, including the granting of a patent by the China National Intellectual Property Administration (CNIPA) for its iPSC-based technology. This development expands the company's patent portfolio, which now includes patents in the US, China, and Japan for their allogeneic chimeric antigen receptor γδ T cells (CAR-γδ T cells) technology, poised to enter phase I clinical trials in Singapore soon.

The company’s immunotherapeutic innovations include the development of synthetic hybrid immune cells, specifically γδ NKT cells, which exhibit receptors from both γδ T cells and NK cells. These cells can recognize a broad spectrum of cancers without genetic modification, offering a potent 'off-the-shelf' therapy option for numerous patients.

CytoMed’s financial health remains robust. For the first half of 2023, the company reported a net loss of S$1.16M ($860,695), excluding IPO-related expenses. As of June 30, 2023, CytoMed had cash and cash equivalents amounting to S$10.44M ($7.72M). The company also raised S$12.94M ($9.57M) from its NASDAQ IPO in April 2023.

Furthermore, CytoMed has entered into strategic collaborations to advance its clinical objectives. Notably, it has partnered with Sengkang General Hospital in Singapore for a proof-of-concept trial using umbilical cord-derived mesenchymal stem cells (UC-MSCs) for cartilage regeneration, addressing osteoarthritis of the knee.

CytoMed Therapeutics continues to make strides in the field of cell-based immunotherapies, with their innovative efforts promising substantial advancements in cancer treatment and regenerative medicine.